Context Therapeutics® Announces Acceptance of Five Abstracts to be Presented at … – Press Release

[ad_1]

PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) — Context Therapeutics Inc. (“Context” or the “Company”) (NASDAQ:CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for Cancer Research (AACR) Annual Meeting 2022, taking place April 8-13, 2022, at the Ernest N. Morial Convention Center in New Orleans, LA.

“Context is committed to advancing new therapeutics for female cancers and we are proud to have our compounds showcased at the upcoming AACR Annual Meeting,” said Martin Lehr, CEO of Context Therapeutics. “We look forward to the presentations from investigators on lead product candidate onapristone extended release (ONA-XR), a potent, specific progesterone receptor (PR) antagonist being evaluated for PR+ breast, ovarian and endometrial cancer, and our preclinical anti-claudin 6 (CLDN6) bispecific monoclonal antibody (BsMAb) for gynecologic cancer therapy.”

Details of the presentations are as follows:

Title: Atomic-level specificity of Claudin 6 monoclonal antibodies isolated for treating solid tumors
Session Category: Experimental and Molecular Therapeutics
Session Title: Antibodies and Immune Therapies
Abstract Number: 318
Presenter: Joseph Rucker, Ph.D., Integral Molecular
Date and Time: April 10, 2022, 1:30 – 5:00 p.m.

Title: Targeting progesterone receptor (PR) with the antiprogestin onapristone in patient-derived xenograft (PDX) models of estrogen receptor positive (ER+), PR positive (PR+) bone metastasis of breast cancer
Session Category: Minisymposium
Session Title: New Approaches to Targeting Hormone Dependent Cancers
Abstract Number: 649
Presenter: Elisabetta Marangoni, Ph.D., Institut Curie
Date and Time: April 10, 2022, 3:00 – 5:00 p.m.

Title: Progesterone promotes immunomodulation and tumor development in the murine mammary gland
Session…

[ad_2]